METROPOLIS HEALTHCARE Q4 BIZ UPDATE
In Q4, the healthcare industry saw weaker performance due to fewer outpatient visits and elective procedures.
Despite this, the company posted double-digit revenue growth, driven by strong performance in the wellness segment.
Revenue grew 10% YoY driven by higher patient and test volumes, better product mix, and improved realizations.
B2C revenue rose 14% YoY due to better consumer experience and network expansion.
Operational EBITDA grew slightly but was impacted by higher material costs and slower revenue growth; reported EBITDA declined due to one-time acquisition costs and lower margins from Core Diagnostics.
The company remains debt-free with INR 112 crore in cash post a INR 130 crore acquisition.
Core Diagnostics contributed 11 days of break-even EBITDA in the quarter.
In Q4, the healthcare industry saw weaker performance due to fewer outpatient visits and elective procedures.
Despite this, the company posted double-digit revenue growth, driven by strong performance in the wellness segment.
Revenue grew 10% YoY driven by higher patient and test volumes, better product mix, and improved realizations.
B2C revenue rose 14% YoY due to better consumer experience and network expansion.
Operational EBITDA grew slightly but was impacted by higher material costs and slower revenue growth; reported EBITDA declined due to one-time acquisition costs and lower margins from Core Diagnostics.
The company remains debt-free with INR 112 crore in cash post a INR 130 crore acquisition.
Core Diagnostics contributed 11 days of break-even EBITDA in the quarter.
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
